Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Non-Current Debt (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Non-Current Debt for 6 consecutive years, with $49.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Debt fell 50.74% to $49.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $49.4 million, a 50.74% decrease, with the full-year FY2025 number at $49.4 million, down 50.74% from a year prior.
  • Non-Current Debt was $49.4 million for Q4 2025 at Lexicon Pharmaceuticals, down from $56.5 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $100.3 million in Q4 2024 to a low of $48.8 million in Q1 2023.
  • A 3-year average of $80.6 million and a median of $99.0 million in 2023 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: skyrocketed 104.52% in 2024, then tumbled 50.74% in 2025.
  • Lexicon Pharmaceuticals' Non-Current Debt stood at $99.5 million in 2023, then rose by 0.79% to $100.3 million in 2024, then crashed by 50.74% to $49.4 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Non-Current Debt are $49.4 million (Q4 2025), $56.5 million (Q3 2025), and $56.1 million (Q2 2025).